Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Regeneron Pharmaceuticals Inc., consolidated balance sheet: assets (quarterly data)

US$ in thousands

	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cash and cash equivalents	1,995,800)	3,090,200)	2,488,200)	2,011,800)	1,920,700)	2,602,000)	2,730,000)	2,152,300)	1,937,200)	3,916,300)	3,105,900)	3,491,300)	3,395,100)	3,345,700)	2,885,600)	3,432,400)	2,072,200)	1,437,900)	2,193,700)	1,573,000)	1,992,200)	2,208,200)
Marketable securities	5,473,800)	5,259,200)	6,524,300)	7,784,700)	7,888,300)	7,917,500)	8,114,800)	7,761,300)	6,990,500)	5,043,400)	4,636,400)	3,530,400)	4,171,300)	3,704,900)	2,809,100)	2,355,200)	1,838,600)	2,065,900)	1,393,300)	1,452,900)	1,152,000)	1,795,200)
Accounts receivable, net	5,610,000)	5,561,000)	6,211,900)	6,107,100)	5,717,100)	5,222,200)	5,667,300)	5,584,500)	5,121,300)	5,118,600)	5,328,700)	5,548,300)	5,161,400)	4,839,000)	6,036,500)	5,452,000)	6,998,600)	4,173,000)	4,114,700)	4,039,500)	2,811,300)	2,933,200)
Inventories	3,205,600)	3,192,400)	3,087,300)	3,018,000)	2,873,600)	2,714,900)	2,580,500)	2,562,000)	2,507,700)	2,424,700)	2,401,900)	2,412,200)	2,218,500)	1,991,500)	1,951,300)	2,053,800)	1,983,900)	2,164,700)	1,916,600)	1,801,600)	1,640,900)	1,480,900)
Prepaid expenses and other current assets	574,300)	468,900)	349,200)	412,000)	681,900)	414,900)	386,600)	574,700)	366,300)	406,200)	411,200)	446,400)	583,600)	424,900)	332,400)	482,000)	444,300)	213,600)	160,800)	230,600)	263,800)	226,600)
Current assets	16,859,500)	17,571,700)	18,660,900)	19,333,600)	19,081,600)	18,871,500)	19,479,200)	18,634,800)	16,923,000)	16,909,200)	15,884,100)	15,428,600)	15,529,900)	14,306,000)	14,014,900)	13,775,400)	13,337,600)	10,055,100)	9,779,100)	9,097,600)	7,860,200)	8,644,100)
Marketable securities	10,058,200)	9,276,300)	8,900,100)	8,490,900)	7,722,400)	6,978,800)	5,396,500)	5,778,500)	6,327,200)	6,066,600)	6,591,800)	5,968,600)	6,415,900)	7,084,000)	6,838,000)	5,631,300)	3,900,300)	3,543,700)	3,135,600)	2,875,100)	2,587,600)	3,236,400)
Property, plant, and equipment, net	4,840,700)	4,694,200)	4,599,700)	4,439,200)	4,305,900)	4,225,500)	4,146,400)	4,006,100)	3,922,600)	3,880,900)	3,763,000)	3,704,200)	3,637,700)	3,556,400)	3,482,200)	3,395,700)	3,358,500)	3,262,600)	3,221,600)	3,138,300)	3,031,400)	2,944,600)
Intangible assets, net	1,351,700)	1,167,000)	1,148,600)	1,120,100)	1,102,200)	1,058,700)	1,038,600)	1,017,200)	953,000)	928,700)	915,500)	804,100)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Deferred tax assets	3,572,200)	3,442,900)	3,314,100)	3,015,100)	2,880,900)	2,764,900)	2,575,400)	2,316,800)	2,138,500)	1,924,900)	1,723,700)	1,452,100)	1,352,400)	1,140,300)	876,900)	723,200)	746,600)	765,100)	858,900)	804,200)	774,000)	771,200)
Other noncurrent assets	1,536,900)	1,393,100)	1,136,000)	1,043,000)	993,800)	470,200)	444,100)	409,900)	393,200)	349,600)	336,400)	320,200)	269,900)	262,000)	222,800)	145,900)	142,900)	145,700)	168,100)	168,800)	175,500)	161,200)
Noncurrent assets	21,359,700)	19,973,500)	19,098,500)	18,108,300)	17,005,200)	15,498,100)	13,601,000)	13,528,500)	13,734,500)	13,150,700)	13,330,400)	12,249,200)	11,675,900)	12,042,700)	11,419,900)	9,896,100)	8,148,300)	7,717,100)	7,384,200)	6,986,400)	6,568,500)	7,113,400)
Total assets	38,219,200)	37,545,200)	37,759,400)	37,441,900)	36,086,800)	34,369,600)	33,080,200)	32,163,300)	30,657,500)	30,059,900)	29,214,500)	27,677,800)	27,205,800)	26,348,700)	25,434,800)	23,671,500)	21,485,900)	17,772,200)	17,163,300)	16,084,000)	14,428,700)	15,757,500)

The financial data presents a comprehensive overview of the company's asset structure and evolution over a series of quarterly periods. Observing the trends in current assets, noncurrent assets, and total assets reveals several key patterns.

Current Assets: Current assets exhibit a fluctuating but overall upward trajectory from approximately 8.64 billion USD in Q1 2020 to a peak around 19 billion USD in mid-2023, followed by a decline to approximately 16.86 billion USD by mid-2025. This increase is mainly driven by marketable securities and accounts receivable, both showing substantial growth.
Cash and Cash Equivalents: Cash and cash equivalents demonstrate considerable volatility throughout the periods, dropping from about 2.2 billion USD in early 2020 to a low near 1.44 billion USD in Q1 2021, then rallying to peaks above 3.9 billion USD by early 2023. Subsequently, it declines sharply again, reaching roughly 1.99 billion USD by mid-2025. This fluctuation suggests active liquidity management or possible timing of cash flows.
Marketable Securities: Marketable securities, split into two reported lines, show significant growth from approximately 3.2 billion USD in early 2020 to over 10 billion USD by mid-2025. The increase is steady with some peaks in late 2021 and late 2024, highlighting a growing portfolio of liquid investments or possibly increased cash prudence.
Accounts Receivable, Net: Accounts receivable initially fluctuated, with a notable jump in mid-2021 to nearly 7 billion USD, followed by a somewhat stable range between 5.5 and 6.2 billion USD thereafter. The rise in mid-2021 may indicate increased sales or extended credit terms. Subsequent stability suggests normalization or consistent revenue collection patterns.
Inventories: Inventories steadily grow from around 1.5 billion USD at the beginning of the period to over 3.2 billion USD by mid-2025. This continuous increase may reflect expanded production capacity, stockpiling, or preparation for higher sales volumes.
Prepaid Expenses and Other Current Assets: These fluctuate considerably, starting near 227 million USD in early 2020, peaking multiple times above 600 million USD, and ending near 574 million USD by mid-2025. The variation may relate to changes in operational costs or timing of purchases and services prepayments.
Property, Plant, and Equipment, Net: This category shows steady growth from approximately 2.94 billion USD in the first quarter of 2020 to about 4.84 billion USD by mid-2025, indicating ongoing capital investments in fixed assets and expansion of operational infrastructure.
Intangible Assets, Net: Intangible assets begin to be reported from late 2022 at around 804 million USD, growing gradually to approximately 1.35 billion USD by mid-2025, reflecting likely acquisitions, capitalized research, or development costs increasing the value of intangible holdings.
Deferred Tax Assets: Deferred tax assets trend upward from about 771 million USD in early 2020 to over 3.5 billion USD by mid-2025. This continuous increase suggests accumulating deductible temporary differences or tax credit carryforwards that can reduce future tax liabilities.
Other Noncurrent Assets: Other noncurrent assets show a consistent rise from roughly 161 million USD to about 1.54 billion USD over the presented period, indicating diversification in long-term holdings or investments beyond tangible and intangible core assets.
Total Assets: Total assets increase significantly from approximately 15.76 billion USD in early 2020 to a high near 38.22 billion USD by mid-2025. This growth is driven by expansions in both current and noncurrent assets, reflecting overall company growth and capital deployment.

In summary, the company has experienced substantial asset growth across nearly all categories over the reported quarters. The rise in marketable securities and cash positions suggests prudent liquidity management. The steady increases in inventories, property, plant, and equipment, as well as intangible assets, indicate ongoing investment in operational capacity and intellectual property. The growth in deferred tax assets and other noncurrent assets points to strengthening future tax benefits and diversified asset holdings. Despite some volatility in cash balances and prepaid expenses, the general trend reflects expansion and asset base strengthening.

Assets: Selected Items

Download chart

Current Assets: Selected Items

Download chart

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Balance Sheet: Assets Quarterly Data

Assets: Selected Items

Current Assets: Selected Items

Balance Sheet: Assets
Quarterly Data